Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (1): 47-49.
• Orignal Article • Previous Articles Next Articles
YU Hao1, ZHOU Yong-gang2, *, LI Xiao-wei2, WANG You-qun1
Received:
2016-02-03
Revised:
2016-02-03
Online:
2014-01-08
Published:
2016-02-03
CLC Number:
YU Hao, ZHOU Yong-gang, LI Xiao-wei, WANG You-qun. Effect of Strengthened Drug Education by Clinical pharmacist on Survival, Rehospitalization and Reoperation Rate of Coronary Heart Disease Patients[J]. Chinese Journal of Pharmacovigilance, 2014, 11(1): 47-49.
Add to citation manager EndNote|Ris|BibTeX
[1] 王朝晖. 重视高龄老人冠心病诊治特点[J]. 临床心血管病杂志, 2012, 28(7): 481-483. [2] WHO. Global strategy on diet, physical activity and health[EB/OL].(2009-04-30)[2013-06-01].http://www.who.int/dietphysicalactivity/ goals/en/index.html. [3] 中华医学会心血管病学分会. 中国心血管病预防指南[J]. 中华心血管病杂志, 2011, 39(1): 3-22. [4] 王贵芝, 高鹤南, 熊薇, 等. 护士在冠心病二级预防中的作用[J]. 中华护理杂志, 2001, 36(7): 515-516. [5] Hymel P, Loeppke R, Baase C, et al. Establishing a research agenda in health and productivity[J]. Journal of Occupational and Environmental Medicine, 2004, 46(6): 518-520. [6] 蒙凯凤,黄萍.电话随访冠心病病人二级预防的效果分析[J]. 内科, 2008, 3(5): 812-813. [7] 姜风华,刘理慧, 姜光红.电话随访在中青年冠心病患者遵医行为中的作用[J]. 齐鲁护理杂志, 2009, 15(011): 16-18. [8] 陇文菊.电话回访式健康教育对老年冠心病患者生活质量的影响[J].中国老年学杂志, 2010, 30(7): 975-976. [9] Hwang S S, Barfield W D, Smith R A, et al. Discharge Timing, Outpatient Follow-up, and Home Care of Late-Preterm and Early-Term Infants[J]. Pediatrics, 2013 ,132(1):101-108. |
[1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
[2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
[3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
[4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
[6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
[7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
[8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
[9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
[10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
[11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
[12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
[13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
[14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
[15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||